$0.65 EPS Expected for CURO Group Holdings Corp. (CURO); Last Week IntelliPharmaCeutics International Inc. (IPCI) Analysts

April 17, 2018 - By Ellis Scott

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Logo

Analysts expect CURO Group Holdings Corp. (NYSE:CURO) to report $0.65 EPS on April, 26 after the close.CURO’s profit would be $29.61 million giving it 6.83 P/E if the $0.65 EPS is correct. After having $0.33 EPS previously, CURO Group Holdings Corp.’s analysts see 96.97% EPS growth. The stock decreased 1.39% or $0.25 during the last trading session, reaching $17.75. About 167,973 shares traded. CURO Group Holdings Corp. (NYSE:CURO) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Among 2 analysts covering Intellipharmaceutics Intl (NASDAQ:IPCI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Intellipharmaceutics Intl had 8 analyst reports since December 31, 2015 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Monday, February 12 with “Buy”. The firm has “Buy” rating by Maxim Group given on Tuesday, June 6. Maxim Group maintained it with “Buy” rating and $600 target in Friday, July 21 report. H.C. Wainwright maintained the shares of IPCI in report on Monday, March 5 with “Buy” rating. On Friday, February 16 the stock rating was downgraded by Maxim Group to “Hold”. On Thursday, December 31 the stock rating was maintained by Maxim Group with “Buy”. The stock has “Buy” rating by Maxim Group on Friday, June 30. See IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) latest ratings:

05/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $2.5 Maintain
16/02/2018 Broker: Maxim Group Rating: Hold Downgrade
12/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $2.5 Maintain
19/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $2.5 Initiates Coverage On

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and makes novel and generic controlled-release and targeted-release oral solid dosage drugs in Canada. The company has market cap of $25.81 million. It develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. It currently has negative earnings. The companyÂ’s lead product is Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for attention deficit hyperactivity disorders.

The stock decreased 0.41% or $0.002 during the last trading session, reaching $0.609. About 132,297 shares traded. IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) has declined 75.33% since April 17, 2017 and is downtrending. It has underperformed by 86.88% the S&P500.

CURO Group Holdings Corp. provides consumer finance to a range of underbanked clients in the United States, Canada, and the United Kingdom. The company has market cap of $808.72 million. It offers unsecured installment loans, secured installment loans, open-end loans, and single-pay loans, as well as ancillary financial products, including check cashing, proprietary reloadable prepaid debit cards, credit protection insurance, gold buying, retail installment sales, and money transfer services. It has a 14.2 P/E ratio. The firm operates under the Speedy Cash, Rapid Cash, Avio Credit, and Cash Money brands; and online as Wage Day Advance, as well as offers installment loans online under the LendDirect brand.

IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>